Table 1.

The PRO instruments conducted in ATLAS and FLAIR

PRO instrument	Assessment	Timepoints measured	Pooled analysis
HIVTSQs/ca	Patient satisfaction with HIV treatment	Status version: maintenance baseline, week 4, week 24, week 44 Change version: week 48	✔
ACCEPT	Patient acceptance of treatment	Maintenance baseline, week 8, week 24, week 48	✔
PIN questionnaire	Perception of pain and injection site reactions	Week 5, week 41, week 48	✔
SF-12	General health status and degree of mental health distress	Maintenance baseline, week 24, week 48	✖
Preference of HIV treatment (single question)	Patient preference for CAB + RPV LA vs. their current oral therapy	Week 48	✖
Reason for switch (single question)	Patient reasoning for switching to LA therapy from oral therapy for ATLAS study only	Week 52	✖
HAT-QoLb	Overall function and wellbeing. Only 3 out of 9 dimensions were assessed	Maintenance baseline, week 24, week 48	✖
Numeric Rating Scalec	Intensity of post-injection pain	Week 4, week 5, week 40, week 41	✖

ACCEPT Chronic Treatment Acceptance questionnaire, CAB cabotegravir, HAT-QoL HIV/AIDS-targeted quality of life, HIVTSQs/c HIV Treatment Satisfaction Questionnaire (status version)/(change version), LA long-acting, PIN Perception of Injection questionnaire, PRO patient-reported outcome, RPV rilpivirine, SF-12 12-Item Short Form Health Survey

^aHIVTSQc only administered to participants receiving LA therapy

^bNo meaningful differences between arms were reported with the three dimensions included in the phase 3 studies. Results are not discussed here

^cConsistent with the PIN, numerical reduction in post-injection pain was reported in the Numeric Rating Scale over time. No significance testing was preplanned for this measure. Results are not discussed here